Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration
- PMID: 20543764
- DOI: 10.1097/IAE.0b013e3181d87e97
Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration
Abstract
Purpose: The purpose of this study was to evaluate the effect of intravitreally administered bevacizumab on untreated vascularized pigment epithelium detachment (PED) in sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration.
Methods: In this retrospective study, 28 untreated eyes of 26 patients (4 men, 22 women; mean age, 74.6 ± 7.2 years) with PED and sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration and additional intra- and/or subretinal fluid were treated with intravitreal injections of 1.25 mg bevacizumab. Baseline and follow-up visits included best-corrected visual acuity, complete ophthalmic examination, and Stratus optical coherence tomography. Fluorescein angiography was performed at baseline. Reinjections were performed if intra- and/or subretinal fluid persisted or recurred or PED increased.
Results: Patients received 3.2 ± 1.8 injections (follow-up 37.9 ± 18.3 weeks). Mean maximum PED height showed a tendency to decrease (372 ± 150.5 μm to 290.3 ± 189 μm; P = 0.094). In 14 eyes (53.8%), PED height was reduced at last visit, including complete flattening in 1 eye. Mean visual acuity remained stable (0.58 ± 0.30 logarithm of the minimum angle of resolution to 0.58 ± 0.37 logarithm of the minimum angle of resolution; P = 0.905). Pigment epithelium detachment response to treatment did not correlate with baseline PED height or visual acuity at baseline or at the last visit. One patient sustained a retinal pigment epithelium rip, and another patient sustained an extensive subretinal hemorrhage.
Conclusion: During bevacizumab therapy, mean PED height decreases in 50% of patients. No predictive factors for the response of PED to bevacizumab treatment could be identified. Treatment of PED with bevacizumab might result in a long-term functional benefit compared with the natural course.
Similar articles
-
Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.Retina. 2007 Sep;27(7):891-6. doi: 10.1097/IAE.0b013e3180ca9ad9. Retina. 2007. PMID: 17891013
-
Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.Retina. 2011 Oct;31(9):1812-8. doi: 10.1097/IAE.0b013e31821987a4. Retina. 2011. PMID: 21866073
-
Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.Retina. 2007 Jun;27(5):541-51. doi: 10.1097/IAE.0b013e3180cc2612. Retina. 2007. PMID: 17558314
-
Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100. Semin Ophthalmol. 2011. PMID: 21609219 Review.
-
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.Prog Retin Eye Res. 2016 Jan;50:1-24. doi: 10.1016/j.preteyeres.2015.07.007. Epub 2015 Aug 22. Prog Retin Eye Res. 2016. PMID: 26307399 Review.
Cited by
-
High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration.Korean J Ophthalmol. 2016 Aug;30(4):265-71. doi: 10.3341/kjo.2016.30.4.265. Epub 2016 Jul 21. Korean J Ophthalmol. 2016. PMID: 27478353 Free PMC article.
-
Retinal Pigment Epithelial Detachment in Age-Related Macular Degeneration.Ophthalmol Ther. 2020 Dec;9(4):739-756. doi: 10.1007/s40123-020-00291-5. Epub 2020 Aug 18. Ophthalmol Ther. 2020. PMID: 32809132 Free PMC article. Review.
-
Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample.J Med Life. 2023 Feb;16(2):235-243. doi: 10.25122/jml-2022-0356. J Med Life. 2023. PMID: 36937463 Free PMC article.
-
Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors.Pharmaceuticals (Basel). 2021 Oct 13;14(10):1042. doi: 10.3390/ph14101042. Pharmaceuticals (Basel). 2021. PMID: 34681267 Free PMC article.
-
OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review.J Ophthalmol. 2021 Jul 17;2021:9994098. doi: 10.1155/2021/9994098. eCollection 2021. J Ophthalmol. 2021. PMID: 34336265 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous